 The study estimates that the inclusion of PCV7 and PCV13 in Mexico's National Immunization Program has prevented over 1.5 million cases of pneumococcal disease and 1,854 deaths, resulting in a net savings of 4.5 billion Mexican pesos. Continued use of PCV13 is estimated to save over 300,000 cases of pneumococcal disease and 373 deaths compared to switching to PCV10 over a 10-year period with a cost saving of 0.71 billion MXN. The study concludes that the PCV program in Mexico has provided a significant return on investment and sustained use of PCV13 is estimated to provide the greatest healthcare and economic impact. This article was authored by Matthew Wasserman, Maria Gabriela Palacios, Anna Gabriela Guajales and others. We are article.tv, links in the description below.